rimonabant also known trade names acomplia anorectic antiobesity drug approved europe withdrawn worldwide due serious psychiatric side effects never approved united rimonabant inverse agonist cannabinoid receptor firstinclass clinical rimonabant selective receptor blocker discovered developed june european commission approved sale rimonabant european union prescription drug use conjunction diet exercise patients body mass index bmi greater patients bmi greater associated risk factors type diabetes first class approved anywhere rimonabant submitted food drug administration fda approval united states fdas endocrine metabolic drugs advisory committee emdac concluded sanofiaventis failed demonstrate safety rimonabant voted recommending antiobesity treatment application deemed notapprovable fda company cancelled plans drug approved brazil april october european medicines agency recommended suspension acomplia committee medicinal products human use chmp determined risks acomplia outweighed benefits due risk serious psychiatric problems including november advisory committee brazil recommended suspension well month sanofiaventis suspended sale drug ema approval withdrawn january india prohibited manufacture sale data clinical trials submitted regulatory authorities showed rimonabant caused depressive disorders mood alterations subjects suicidal ideation around europe contraindicated people psychiatric disorder including depressed suicidal data large randomized clinical trial crescendo patients receiving rimonabant treatment demonstrated rate psychiatric adverse events anxiety depression depressed mood insomnia greater additionally nausea upper respiratory tract infections common adverse effects occurring people common adverse effects occurring people included gastroenteritis anxiety irritability insomnia sleep disorders hot flushes diarrhea vomiting dry itchy skin tendonitis muscle cramps spasms fatigue flulike symptoms increased risk falling fdas advisory committee concurred concerns raised review divisions based human animal data appeared therapeutic window regard cns toxicity specifically seizures ema postmarketing surveillance data suggested risk psychiatric disorders people taking rimonabant rimonabant inverse agonist cannabinoid receptor originally thought selective receptor rimonabant subsequently also found act antagonist Î¼opioid chemical synthesis rimonabant described verification along clinical trials obesity generated data submitted regulatory rimonabant also studied clinical diabetes atherosclerosis smoking httpsenwikipediaorgwikirimonabant